Zhejiang Wolwo Bio-Pharmaceutical announced that the company downloaded the "Drug Clinical Trial Approval Notice" from the online service hall of the National Medical Products Administration, and the clinical trial application for the "house dust mite membrane agent" submitted by the company has been approved. This product is classified as a Class 1 Biological Product for therapeutic use, suitable for adult patients with allergic rhinitis related to dust mite sensitivity (with or without allergic conjunctivitis or allergic asthma). The company is actively preparing for the Phase I clinical trial of this product.
我武生物：公司“屋尘螨膜剂”药物临床试验申请获得批准
Zhejiang Wolwo Bio-Pharmaceutical: The company's clinical trial application for the "house dust mite membrane agent" has been approved.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney